Particle.news
Download on the App Store

Stiko Lowers Shingles Vaccine Age to 18 for At-Risk Adults

The update aims to prevent severe, potentially life‑threatening cases in people with weakened immune systems.

Overview

  • Eligibility now includes adults from 18 with risk factors such as diabetes, HIV, chronic inflammatory bowel disease, or a history of blood‑stem‑cell transplant.
  • The prior threshold for risk groups was 50, and the universal recommendation for everyone 60 and older remains unchanged since 2018.
  • The vaccine course consists of two doses given within a maximum interval of six months.
  • Shingles results from reactivation of the varicella‑zoster virus and can disseminate in immunocompromised patients, according to the RKI.
  • The revised guidance was published on 7 November in the Robert Koch Institute’s Epidemiologisches Bulletin.